This MM line shows low tumor-mutational burden, a lack of known oncogenic drivers, and is chemo-resistant to the vast majority of compounds currently approved for the melanoma treatment (BRAFi/MEKi, C-KIT inhibitors, anti-angiogenic kinase inhibitors, DNA-alkylating agents) [78]. This evidence concerns the gene KIT and melanoma.